AcuCort

AcuCort’s Phase IV trial ZEQ001 commenced in late January 2024 with the objective of generating real-world evidence from patients transitioning from traditional tablet formulations to Zeqmelit®. The trial focused on evaluating patient experiences with the product, including perceived safety, ease of use, and overall convenience in daily life.

As previously disclosed by AcuCort, the last patient completed the study in November 2024. Following the conclusion of the trial, a comprehensive data analysis was conducted, culminating in the development of a detailed clinical study report. This report now serves as the foundation for drafting scientific publications aimed at allergists and other specialists managing this patient population.

“The results from this study are highly positive and provide a robust basis for scientific dissemination. Publications in international peer-reviewed journals are a cornerstone of our strategy to establish Zeqmelit® as treatment option in both European and U.S. markets,” says Jonas Jönmark, CEO of AcuCort.

For further information:
Jonas Jönmark, vd, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)

AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.